New drug aims to shield patients from chemo side effects in bladder cancer battle
NCT ID NCT07484022
Summary
This early-stage study is testing whether adding an investigational drug called GB-4362 to a standard two-drug regimen can make treatment safer for adults with advanced bladder cancer. GB-4362 is designed to neutralize a specific chemotherapy component that causes side effects like nerve damage, potentially allowing patients to stay on their cancer-fighting drugs longer. The main goal is to find a safe dose and see if GB-4362 successfully reduces the levels of this harmful component in the blood.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC UROTHELIAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Start New York, LLC
Lake Success, New York, 11042, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.